Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering

Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This might reflect current reagents delivering suboptimal CD27 agonism. Here, using a novel panel of CD27 mAb including a clinical candidate, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Heckel, Franziska, Turaj, Anna H., Fisher, Hayden, Chan, H. T. Claude, Marshall, Michael J. E., Dadas, Osman, Penfold, Christine A., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Alvarado, Diego, Tews, Ivo, Keler, Tibor, Beers, Stephen A., Cragg, Mark S., Lim, Sean H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921514/
https://www.ncbi.nlm.nih.gov/pubmed/35288635
http://dx.doi.org/10.1038/s42003-022-03182-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921514/
https://www.ncbi.nlm.nih.gov/pubmed/35288635
http://dx.doi.org/10.1038/s42003-022-03182-6

Ejemplares similares